Dose Escalation and Associated Predictors of Survival with Consolidative Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer (SCLC): A National Cancer Database (NCDB) Propensity-Matched Analysis

With a median survival of 6 to 12 months, small cell lung cancer (SCLC) most commonly presents with metastatic or extensive stage (ES) disease [1]. Cisplatin-based doublet chemotherapy is the mainstay of therapy with high rates of initial response. However, a proportion of patients harbor residual intrathoracic disease, precipitating the hypothesis that consolidative thoracic radiotherapy (TRT) can improve outcomes [2]. Several prospective and retrospective studies have demonstrated a survival benefit with the addition of thoracic radiation in ES-SCLC, including the recent phase III CREST trial which reported a 10% 2-year overall survival benefit for consolidative TRT to a dose of 30  Gy in 10 fractions [3–9].

Source: Lung Cancer - August 20, 2018 Category: Cancer & Oncology Authors: Shaakir Hasan, Paul Renz, Andrew Turrisi, Athanasios Colonias, Gene Finley, Rodney E. Wegner Source Type: research